- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive an Additional $32.5
ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
PDUFA Date is November 28, 2022 WALTHAM, Mass. --(BUSINESS WIRE)--May 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 9, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical